Online Medical Reference

Takayasu's Arteritis

Alison Clifford

Gary S. Hoffman

Published: June 2014

Definition and Etiology

Takayasu's arteritis (TA) is a large-vessel vasculitis of unknown etiology that has a predilection for the aorta and its primary branches. Sustained inflammation of involved vessels leads most often to stenotic or occlusive lesions and less often may cause aneurysms.1 Several classification and nomenclature guidelines note that TA affects persons younger than 40 or 50 years, while the diagnosis of giant cell arteritis (GCA) has been said to be most appropriate for those who develop large-vessel vasculitis after the age of 50. These age-based definitions are felt by us and others to be arbitrary, and are not widely accepted by most authors. It has been suggested that these two entities may in fact represent extremes within the same spectrum of disease.

Back to Top


TA is a rare disorder that has been described in people of all races, in most parts of the world. While initially thought to be most prevalent in Asian countries, this data needs to be re-examined to be certain about possible ethnic skewing. The estimated annual incidence in North America is only 2.6 cases per million population.2 Women are affected up to 10 times more often than men, and the peak incidence is in the 3rd decade of life.1

Back to Top


Vascular injury is mediated by the actions of macrophages, cytotoxic T cells, gd T cells, and natural killer cells,3,4 which are the main cellular components of inflammatory infiltrates. The inflammatory process leads to myointimal proliferation, with subsequent vessel wall thickening and luminal stenosis, the most common lesion of TA. Lesions that predominantly cause destruction of the muscularis and the elastic lamina can result in vascular dilatation or aneurysms. Such abnormalities most commonly occur in the aortic root and arch.

Cytokines (such as tumor necrosis factor-alpha [TNF-α], interleukin-6 [IL-6], and interferon-gamma [IFN-γ]), a variety of chemokines, and other proteins (including perforin and matrix metalloproteinases) are involved in induction and amplification of the inflammatory response and tissue injury.3-5 IL-6 and chemokine (C-C motif) ligand 5 (CCL5 or RANTES) serum levels are roughly associated with disease activity in TA patients.6 In addition, it is well known that TNF-α plays an important role in granuloma formation, and TNF-α can be demonstrated within the vessel wall in large-vessel vasculitis.7 Compared with normal controls, messenger RNA for TNF is increased in peripheral blood mononuclear cells of TA patients.5,8,9 Serum TNF-α5,8,9 is similarly increased in TA patients compared with healthy persons, and a potential role for TNF-α in the pathogenesis of TA is suggested by the efficacy of anti–TNF-α therapies in patients with refractory TA.10

Back to Top

Signs and Symptoms

One of the difficulties in making a diagnosis of TA lies in the heterogeneity of presentations. TA manifests with clinically nonspecific signs and symptoms of systemic inflammation in about 50% of patients.11 These include fever, weight loss, malaise, and generalized arthralgias and myalgias. The most common symptoms and signs of TA in different cohorts of patients (Americans,1,11 Italians,12 Mexicans,13 and Indians14) have been reviewed.11 Diminishing or absence of pulse or blood pressure, or asymmetry of blood pressure in upper or lower extremities; bruits (most often found over the carotid, subclavian, abdominal, and femoral arteries); claudication of extremities; fatigue; and headache are present at the time of disease onset in about half of patients.11 The most commonly involved arterial territories in American cohorts are the aorta and subclavian arteries (see Figure 1), followed by carotid, mesenteric, iliofemoral, and vertebral arteries.11

Symptomatic involvement of coronary and pulmonary arteries is less commonly detected.11 However, imaging of pulmonary vasculature has shown evidence of involvement in more than 50% of cases.15,16 Stenotic vascular lesions are found in more than 90% of patients; dilatation or aneurysm formation makes up 17% to 25% of lesions.11,12 The aortic root is the most common location for aneurysmal disease (see Figure 2) and can lead to clinically apparent valvular regurgitation, which occurs in a quarter of patients.11 Rupture of an aortic arch aneurysm and congestive cardiac failure due to aortic insufficiency or hypertension are two main causes of death in TA patients.1,11,12

Hypertension is a major source of disease-related morbidity and is present in at least 40% of U.S. and European patients.11,12 Hypertension has been noted in up to 80% of patients from India, Japan, Mexico, and Korea.11 Renal artery stenosis (Figure 3) is present in 25% to 80% of patients and is the most common cause of hypertension,11 which can also result from suprarenal aortic stenosis or decreased aortic compliance.17

Neurologic symptoms are present in more than 50% of patients.11 These symptoms can result from stenosis of carotid or vertebral arteries (Figure 4a-b), which also causes dizziness, syncope, vertigo, and orthostatic symptoms. More severe manifestations such as transient ischemic attack (TIA) or stroke are seen in up to 5% to 10% of patients and are more often experienced by patients with carotid or vertebral disease. Severe or atypical headache occurs in 40% to 57% of patients.11

Although visual disturbances including amaurosis fugax and permanent blindness have been described in 12% to 30% of some TA series,1,11,18 permanent loss of vision is quite uncommon in North American patients.1,11 Hypoperfusion of retinal and choroidal vessels due to stenosis of carotid arteries is responsible for TA retinopathy, which is characterized by dilation of small vessels; formation of microaneurysms and arteriovenous anastomoses; and neovascularization of the retina. Its reported incidence is 14% to 33% in Asian patients.18 Hypertensive retinopathy and glucocorticoid adverse events affecting eyes (e.g., glaucoma, cataracts) are common in TA and also need to be considered in these patients.

Pulmonary involvement in TA is characterized by vasculitis affecting the large- or medium-sized pulmonary arteries. These abnormalities (occlusion, stenosis, and post-stenotic dilatation) are detected in more than 55% of TA patients on imaging studies,15,16 but most are asymptomatic. Manifestations of pulmonary vascular involvement can become apparent years before the systemic arterial disease has been suspected. Clinical symptoms such as hemoptysis, dyspnea, cough, or chest pain occur in about 25% of patients. Shortness of breath, not clinically attributable to cardiac or pulmonary disease, affects almost 20% of patients.17 Rare cases of TA with interstitial pneumonitis, pleural effusion, massive hemoptysis, and thrombosis of pulmonary arteries have been reported.16,19 Perfusion lung scans can be abnormal in 76% of patients20 and mimic chronic thromboembolic disease. In these cases, the differential diagnosis of both entities needs to be considered.19

Visceral artery involvement is described in 20% to 40% of cases.11 Lesions of the celiac trunk or mesenteric arteries can result in ischemia of the abdominal viscera. Because development of collateral vessels is the rule, symptoms usually do not occur unless at least two of the three main mesenteric vessels (celiac, superior mesenteric, and inferior mesenteric arteries) are compromised. Dermatologic manifestations are noted in up to 28% of patients. Although rare cases of cutaneous necrotizing and granulomatous vasculitis have been described, more common associations are erythema nodosum, erythema induratum, and pyoderma gangrenosum.21

Back to Top


Because of the rarity of this disease, delays in diagnosis are common. In a recent U.S. cohort, the median delay to diagnosis was 17.5 months (range, 7-41.8 mos), and 44.8 months for those patients over the age of 40.22 The diagnosis of TA relies on clinical findings in the setting of compatible vascular imaging abnormalities.

Laboratory Tests

No serologic tests have sufficient sensitivity and specificity to be considered a gold standard for diagnosis.23 Although acute-phase reactants may be helpful in assessing disease activity, they are elevated in only 60% to 70% of patients at diagnosis22 and, in many cases, do not correlate with systemic symptoms or progressive change on imaging studies. Normal acute-phase reactants do not ensure disease remission.23 Sequential imaging evaluations have revealed disease progression (as determined by the presence of new vascular lesions in new territories) in more than 50% of patients with clinically stable profiles and normal erythrocyte sedimentation rate (ESR).11,24 Clinical evaluation also underestimates the presence of subclinical disease activity; 44% of patients with TA with apparent clinically quiescent disease undergoing bypass have histopathologic evidence of vascular inflammation.1,22

Vascular Imaging Techniques

Hitherto, the gold standard for supporting the diagnosis of TA has been contrast angiography imaging, which provides information about vessel lumen caliber, permits recording of intravascular pressure measurements, and, when necessary, provides opportunities for intervention (e.g., angioplasty).1 Catheter-directed angiography, however, has limitations, including its inability to provide information about vessel wall thickness. It also carries risks related to arterial invasiveness and rarely injury, intravascular contrast reactions, and renal toxicity. Cardiovascular magnetic resonance (C-MR) with its two components—contrast-enhanced magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA, conventional, or three-dimensional)—is now considered by some to have diagnostic accuracy almost as good as conventional catheter-directed angiography for large-vessel vasculitis. Although measurements of intravascular pressure or intravascular interventions are not possible with C-MR, images can be provided with a good safety profile and without the use of ionizing radiation or nephrotoxic contrast agents. For these reasons, C-MR overall is advantageous for initial diagnosis and for routine sequential follow up for vasculitis involving large vessels.25

Although MRI can provide additional information on the inflammatory status of the vessel wall, the value of the data regarding prediction of vascular anatomic change is uncertain.26,27 Positron emission tomography (PET) imaging using labeled fluorodeoxyglucose has been demonstrated to be useful in identifying the presence or absence of inflammation within large vessels, as well.27,28

Combinations of some of these techniques such as MRI/MRA or computed tomography–angiography with PET are being used with promising results. However, additional studies are needed to more clearly define the performance characteristics of each technique, especially in regard to imaging enhancement and how imaging findings correlate with disease progression when studied longitudinally. Although vessel wall enhancement may suggest inflammation, this remains an assumption; it is suspected that vessel repair and remodeling may also produce similar findings. The accuracy of persistent enhancement in predicting later vessel anatomic change (stenoses or aneurysms) is uncertain.

Histologic Diagnosis

Biopsies of large vessels are usually not practical in the absence of indications for bypass. In that setting, we strongly recommend that a specimen of an involved artery be obtained for histologic examination.29 Lesions can reveal granulomatous arteritis, with lymphoplasmacytic infiltrates, multinucleated giant cells, and cytotoxic and gd T lymphocytes,29–31 as well as patchy destruction of medial musculoelastic lamina and different degrees of adventitial fibrosis and myointimal proliferation (Figure 5a-b).31

Differential Diagnosis

TA can mimic other conditions. Diseases such as Marfan's syndrome, type IV Ehlers-Danlos syndrome, Loeys-Dietz, and other congenital disorders of connective tissue can manifest with aneurysmal disease and aortic valve insufficiency. However, these diseases are not associated with large-vessel stenoses, the hallmark of TA. In addition, signs and symptoms of systemic inflammation are absent in genetic vascular disorders of collagen and fibrillin synthesis, for which the histologic finding is cystic medial degeneration.

Fibromuscular dysplasia (FMD) is a non-inflammatory, non-atherosclerotic vascular disease, which results in arterial stenoses, aneurysms, and/or dissections of medium-sized arteries. There are several forms of FMD, of which multifocal FMD is the most common (>90%).32 Middle-aged females are preferentially affected, and although involvement of most arteries has been described, the renal and extracranial carotid and vertebral arteries are most frequently involved. Patients commonly present with hypertension (due to renal artery stenosis), headache, pulsatile tinnitus or TIA/stroke (due to involvement of carotid arteries), or bruits, potentially mimicking either TA or atherosclerotic disease. FMD may be distinguished from TA by the absence of signs of systemic inflammation, and the characteristic angiogram finding of "string of beads" changes in the mid-to-distal portion of arteries (Figure 6a-b).32

Infectious etiologies should be considered in all patients with large-vessel aneurysms. Agents known to cause aortic aneurysms include bacterial, syphilitic, mycobacterial, and mycotic pathogens. Stenotic disease in the setting of infection is uncommon.

Atherosclerotic vascular disease can manifest similarly to TA, but the setting in which these disorders occur differs. TA is more prevalent in young female patients and preferentially affects the large vessels of the upper extremities and the aortic root. Atherosclerosis more often occurs in older persons with vascular risk factors and is more common in the vessels of the lower extremities and abdominal aorta.

Rarely TA initially exhibits pulmonary perfusion scan abnormalities similar to those of chronic thromboembolic disease. TA needs to be ruled out when insidious progressive or episodic dyspnea occurs, in conjunction with multiple segmental pulmonary perfusion defects in a young patient.

Other vasculitides such as Cogan's syndrome, Behçet's syndrome, systemic lupus erythematosus (SLE), sarcoidosis, and the spondyloarthropathies may be associated with large-vessel vasculitis. Fortunately, in most cases their other disease manifestations help to distinguish them from TA.

The overlap between TA and GCA is generally underappreciated. For example, patients with TA might have musculoskeletal features that are similar to those of polymyalgia rheumatica, or they might experience amaurosis, blindness, jaw claudication, or headaches. Distinguishing between the two disorders may be merely a matter of semantics.


  • It is important to be mindful of the heterogeneity of presentations of TA.
  • The diagnosis of TA should be entertained in the setting of symptoms of ischemia or claudication, or with findings of hypertension, absent pulse(s), or asymmetry of blood pressures in a younger patient.
  • In many TA patients, normal acute-phase reactants can be misleading because progressive abnormalities in vascular anatomy can occur in spite of such "reassuring" data.
  • Cardiovascular MR can be used in routine care in TA in the initial diagnosis and during the follow up. Sequential imaging of the entire large-vessel anatomy might detect new lesions or the evolution of previously noted abnormalities.
  • Other diseases, especially congenital and infectious, can mimic large-vessel vasculitis and should be considered in the differential diagnosis.

Back to Top


Assessment of Disease Activity

One of the greatest challenges in managing TA is determining disease activity. Kerr and colleagues1 defined active disease according to the existence of new or worsening of any two or more of the following parameters: signs or symptoms of vascular ischemia or inflammation, increase in sedimentation rate, new angiographic features in new territories, and systemic symptoms not attributable to another disease.

Although these features have been demonstrated to be helpful when present, their absence does not ensure disease remission; that is, they are not adequately sensitive. In addition to routine clinical assessment, it remains imperative that all patients have regular, serial imaging of the large vessels to monitor for new disease activity to guide treatment decision making. When using imaging to assess disease activity, it is important to remember that a lesion resulting from previous inflammation may continue to progress over time (i.e., a stenotic lesion may progress to occlusion, or an aneurysmal lesion may dilate over time) without ongoing inflammation being present. Currently, the best marker for unequivocally active disease remains the development of a new vascular lesion in a previously unaffected territory.

Pharmacologic Therapy

Glucocorticoids are the baseline for treatment of active disease. Initial therapy generally consists of prednisone in dosages of about 1 mg/kg/day. High doses of glucocorticoids result in clinical improvement in almost all patients and lead to remission in about 60%. However, when prednisone is tapered to less than 20 mg/day, most patients suffer relapse.11,24 Between 46% and 84% of patients will require a second agent to achieve and sustain remission.33 Frequently prescribed second-line agents include methotrexate, azathioprine and mycophenolate mofetil.34 Cyclophosphamide (1-2 mg/kg/day orally) may also help to achieve and maintain disease remission. However, because of the risk of severe toxicity with long-term therapy (>3-6 months), this drug is only recommended for patients with severe TA refractory to other immunosuppressive therapy.29,34 When remission has been induced with cyclophosphamide over 3 to 4 months, long-term maintenance of remission should be attempted with methotrexate or azathioprine.29

Minocycline, besides having antimicrobial activity, also suppresses production of metalloproteinases. Minocycline has been used in addition to glucocorticoids in a series of 11 patients with TA. Results were encouraging in regard to reducing levels of acute-phase reactants and improving control of disease activity. However, randomized studies must be done to establish the value of this agent in TA.35

Advances in our understanding of disease pathogenesis have led to the investigation and use of biologic agents in TA, in particular the anti-TNF agents, anti-IL6 receptor antibody tocilizumab, and B-cell targeted therapy rituximab. In a study performed at Cleveland Clinic, Hoffman and colleagues showed anti–TNF-α agents to be efficacious in sustaining glucocorticoid-free remissions in more than 60% of patients with previously refractory TA.10 In an extended study with up to 7 years follow up, the same authors have documented the sustainability of anti–TNF-α therapy in maintaining disease remission long term (median follow up 28 months).36 Since these initial reports, 19 additional case reports and case series have been published and reviewed, describing the use of anti-TNFs in a total of 128 TA patients.37,38 Taken together, these studies suggest that anti-TNF therapy may induce remission in 70% to 90% of TA patients who are unable to do so with prednisone and a non-biologic agent alone.37 Infliximab is the most commonly studied anti-TNF, and we would not recommend extrapolating these results to all agents of this class. In addition, it should be noted that the majority of patients who responded to infliximab did require an increase in dose or reduction in dosing interval over time to sustain remission, and relapses were common in those who discontinued the drug. In addition to the anti-TNF agents, tocilizumab, a recombinant humanized monoclonal antibody against the IL-6 receptor, is gaining popularity for the treatment of refractory TA. Thus far, 41 tocilizumab-treated patients have been described with impressive preliminary results.37–41 Clinical response was seen in 38 of 41 (92.6%), allowing for significant tapering or discontinuation of prednisone in most. Relapse occurred in only 8 of 38 responders (21%), and adverse events were infrequent and mild. It is interesting to note that 11 patients responded to tocilizumab after previously failing anti-TNF therapy, confirming that this drug works via novel pathways and may be of use in anti-TNF non-responders. Because of its anti–IL-6 activity, inflammatory markers may be unreliable for monitoring disease activity after treatment.37 Further study of this drug is warranted.

Although traditionally considered a disease of T cells, some evidence points to a role for B-cell involvement in TA pathogenesis.42–44 Accordingly, use of rituximab has now been reported in six refractory TA patients, with promising results.44–46

Endovascular and Surgical Treatment

Surgical interventions for revascularization in TA patients are indicated for symptomatic coronary artery disease or cervicocranial artery stenosis, uncontrolled hypertension secondary to renal artery stenosis, severe extremity claudication, moderate to severe aortic valve regurgitation, and aortic aneurysm at risk of rupture or dissection.29 Procedures to re-establish flow in stenotic or occluded vessels include surgical use of synthetic grafts or autologous vessel bypass, endarterectomy, and percutaneous transluminal angioplasty (PTA), with or without stenting. Aortic root replacement or repair is employed for aortic insufficiency, which is usually associated with aortic valve replacement for regurgitant flow.29 Although often initially successful, vascular interventions in TA patients are prone to failure due to the ongoing inflammatory process, degree of vessel fibrosis, and length of lesions. Selecting the best intervention for the lesion in question remains a very difficult area and requires the evaluation of an experienced cardiac or vascular surgeon.

In two American longitudinal cohorts, intervention for either vessel stenosis or aortic regurgitation was required in one-half to two-thirds of TA patients over mean periods of 3 to 5 years.1,11 PTA and stenting used alone or as a combined treatment in TA have been reviewed in a study that included 11 series of TA patients and 224 vascular lesions. Patency rate was variable among series.11 In our experience at Cleveland Clinic, a cohort of 30 TA patients was followed for a mean of 3 years and re-evaluated with sequential imaging studies (mean interval between studies, 4.8 months). A total of 64 revascularization procedures were carried out for stenotic vascular lesions. Angioplasty and vascular bypass and reconstruction procedures were performed in 20 and 44 instances, respectively. Overall, bypass grafts had better sustained patency than angioplasty or stent-treated vessels. Restenosis or occlusion after intervention occurred in 78% of angioplasty and 36% of bypass procedures. Bypass was especially successful when it was feasible to use autologous donor vessels.1,47

Since this study, several large TA cohorts have confirmed superior patency rates following bypass grafting as compared to stenting for TA lesions,48–50 with follow up extending out to 6.5 years. In the future, however, advances in surgical techniques such as the use of stent grafts may eventually lead to improved outcomes for endovascular procedures in these patients.51 Although some cases of aortic branch vessel and coronary artery stenosis have been treated with endarterectomy, this procedure is technically difficult or impossible to perform effectively, and it can even be dangerous in TA because arterial lesions can be rigid and often involve the entire thickness of the vessel wall.29

Revascularization should ideally be performed during periods of disease remission. In a retrospective review of 79 TA patients undergoing revascularization, inflammation at the time of intervention was independently associated with arterial complication (odds ratio 7.48, P = 0.04).48 There appears to be a clear benefit to achieving good control of disease activity with the use of immunosuppression both pre- and postoperatively. In a UK cohort of 97 patients with 6 years follow up, outcomes after vascular intervention were significantly better in those who received preoperative immunosuppression. This was particularly true for the group undergoing endovascular repair.49 No patients developed severe complications from the use of perioperative immunosuppression, and no adverse effects on surgical recovery were noted. A second, unrelated study demonstrated that postoperative immunosuppression, with both glucocorticoid and a second agent, independently reduced the risk of re-stenosis after surgery (hazard ratio [HR] 0.41, P = 0.044).52 Whenever possible, we recommend that tissue should be obtained at the time of surgery to help determine disease activity and guide medical therapy.

Reports of surgical risk vary, but risks appear to be increased in patients with TA. One series, following 106 patients over a mean period of 19.8 years, stratified postoperative mortality into early and late deaths. Early deaths, defined as death occurring during hospitalization, occurred in 11% of patients.53 Death occurred in most as a result of cardiovascular complications including congestive heart failure, aneurysm rupture, stroke, or hemorrhage. However, another series of 33 patients reported only one perioperative death (resulting from infection) over a mean follow-up period of 3 years.54 In general, perioperative mortality is influenced by a number of factors, and the experience of the surgical team and medical center in caring for TA patients is a crucial element of surgical success.29

Treatment of Hypertension

Detection and treatment of hypertension in TA are critical in achieving good long-term outcomes. Recognition of hypertension is often delayed because of the high incidence of subclavian and innominate artery stenoses, which can cause falsely low peripheral blood pressure readings in reference to pressure in the aortic root. When stenoses affect all extremities, there might not be any peripheral extremity where blood pressure measurements reflect central aortic pressures. Thus, it is crucial for the clinician to have a map of the entire large-vessel anatomy to identify potential territories at risk and to provide proper care for patients with TA and central hypertension. The importance of complete vascular imaging at the time of diagnosis cannot be overemphasized. When stenoses make reliability of extremity blood pressure recordings questionable, invasive angiography with measurement of central aortic pressure and determination of gradients is critical. In these cases, even when the accuracy of peripheral measurements has been established, identifying a target pressure range that minimizes end-organ damage while allowing vital organ perfusion in the setting of arterial stenoses can be challenging. Close monitoring with avoidance of abrupt decreases in mean pressures is critically important.

Preventive Cardiology and Lifestyle Modification

Persistent inflammation appears to be a risk factor for premature atherosclerosis in a variety of chronic illnesses such as rheumatoid arthritis and SLE. Indeed, when compared with healthy controls, TA patients have increased carotid intima-medial thickness55 and increased arterial stiffness,56 which are surrogate markers for coronary atherosclerosis. Furthermore, intima-medial thickness is increased even in patients with angiographically normal carotid arteries in the setting of active disease.55 Additionally, stenotic and dilated lesions of large- and medium-sized arteries in TA become sites of unusually high turbulence and consequent vascular stress. Areas of turbulent flow have been recognized as foci for arterial atherosclerotic lesions in animal and human studies. These experiences emphasize the importance of identifying, treating, and monitoring all modifiable cardiovascular risk factors in these patients. In addition to vigilant monitoring and controlling hypertension, in the absence of contraindications, anti-platelet therapy should be used. Initially shown to reduce the risk of TIA and ischemic optic neuropathy in patients with GCA, aspirin has now proven protective against TIA, stroke, myocardial infarction, and unstable angina in TA patients as well (HR, 0.055, P = 0.011).57 Although other interventions have not been well-studied to date, a preventative cardiology consultation to address additional screening and manage other cardiovascular risk factors is recommended in all TA patients.


  • Disease activity should be assessed with the combination of clinical manifestations, ESR, and vascular imaging techniques. Better surrogate markers of disease status are needed.
  • Prednisone is the gold standard for initial therapy, but additional agents are needed in most cases. Methotrexate, if not contraindicated, is the preferred second agent.
  • Anti-TNF agents, in particular infliximab, are recommended for TA patients not responding to prednisone and a non-biologic agent. Increased doses or reduced dosing intervals may be required to maintain a response over time. Tocilizumab shows promise for use in refractory TA patients and continues to be investigated.
  • Among revascularization procedures, bypass with autologous vessel grafts has shown better long-term patency than other procedures. However, in many circumstances (e.g., aortic reconstruction), autologous donor vessels are not feasible. When possible, revascularization should be performed when disease is quiescent, and consideration should be given to the use of perioperative immunosuppression.
  • Diagnosis and control of hypertension is critically important. Hypertension is often unrecognized because of stenosis of large vessels supplying blood to the extremities. Hence, comprehensive arterial imaging needs to be performed at the time of diagnosis and sequentially as part of disease surveillance.

Back to Top

Morbidity and Mortality

Chronic morbidity and disability are common in TA1,11 and are directly correlated with the vascular territories involved, frequency of disease relapse, and extent of disease. In addition, there is considerable morbidity associated with immunosuppressive therapies (e.g., infections, hypertension, diabetes, osteoporosis, or cataracts related to use of corticosteroids). Although estimated mean 5-, 10-, and 15-year survival rates are 97%, 97%, and 86% respectively, because it predominantly affects the young, mortality remains increased in TA when compared with the general population, with a standardized mortality ratio of 3.0.22 Fortunately, death from TA is uncommon. When it does occur, in most cases it is the result of cardiovascular complications including congestive heart failure, aneurysm rupture, stroke, or hemorrhage.29,54 Postoperative mortality, defined as death occurring during hospitalization, has been observed in up to 11% of patients52; however, other series have reported few postoperative mortalities.1,11,49

Back to Top

New Perspectives and Special Considerations

Systemic therapies with immunosuppressive and antiproliferative agents (e.g., sirolimus, everolimus) are currently in use in cardiac transplant protocols. These agents target the maladaptive response of intimal hyperplasia that leads to allograft vasculopathy. New stents, impregnated with slow-release forms of these agents, are being used to decrease intimal proliferation and restenosis. Sirolimus-eluting stents have demonstrated higher efficacy than conventional stents in patients with atherosclerotic coronary artery disease, and their mechanism of action has made them of interest in TA. Several case reports have described the use of such drug-eluting stents in TA; however, results have been variable thus far.58–62

Patients with TA require a multidisciplinary approach for optimal care. The team should include rheumatologic, imaging, cardiovascular, and surgical specialists.

Back to Top


TA is a rare, chronic inflammatory disease of the large arteries, leading to vessel stenosis or aneurysm. It is imperative to consider the diagnosis in a younger person presenting with symptoms of ischemia, asymmetrical blood pressures or pulses, or suggestive imaging. Immunosuppressive medications remain the cornerstone of therapy, with surgical interventions reserved for treatment of critical, symptomatic, or life-threatening lesions.

Back to Top

Suggested Readings

  • Park MC, Lee SW, Park YB, et al. Clinical characteristics and outcomes of Takayasu's arteritis: analysis of 108 patients using standardized criteria for diagnosis, activity assessment, and angiographic classification. Scand J Rheumatol 2005; 34:284–292.

Back to Top


  1. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med 1994; 120:919–929.
  2. Hall S, Barr W, Lie JT, Stanson AW, Kazmier FJ, Hunder CG. Takayasu arteritis: a study of 32 North American patients. Medicine (Baltimore) 1985; 64:89–99.
  3. Seko Y, Minota S, Kawasaki A, et al. Perforin-secreting killer cell infiltration and expression of a 65-kD heat-shock protein in aortic tissue of patients with Takayasu's arteritis. J Clin Invest 1994; 93:750–758.
  4. Arnaud L, Kahn JE, Girszyn N,Piette AM, Bletry O. Takayasu's arteritis: an update on physiopathology. Eur J Intern Med 2006; 17:241–246.
  5. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis [published online ahead of print December 7, 2005]. Clin Immunol 2006; 118:154. doi:10.1016/j.clim.2005.09.010.
  6. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100:55–60.
  7. Hernández-Rodríguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis [published online ahead of print December 16, 2003]. Rheumatology (Oxford) 2004; 43:294–301. doi:10.1093/rheumatology/keh058.
  8. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu's arteritis. Clin Exp Immunol 2004; 138:369–374.
  9. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis [published online ahead of print December 13, 2005]. Rheumatology (Oxford) 2006; 45:545–548. doi:10.1093/rheumatology/kei266.
  10. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004; 50:2296–2304.
  11. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 56:1000–1009.
  12. Vanoli M, Daina E, Salvarani C, et al; Itaka Study Group. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 2005; 53:100–107.
  13. Lupi-Herrera E, Sánchez-Torres G, Marcushamer J, Mispireta J, Horwitz S, Vela JE. Takayasu's arteritis: clinical study of 107 cases. Am Heart J 1977; 93:94–103.
  14. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol 1996; 54(suppl):S111–S116.
  15. Yamada I, Shibuya H, Matsubara O, et al. Pulmonary artery disease in Takayasu's arteritis: angiographic findings. AJR Am J Roentgenol 1992; 159:263–269.
  16. Manganelli P, Fietta P, Carotti M, Pesci A, Salaffi F. Respiratory system involvement in systemic vasculitides. Clin Exp Rheumatol 2006; 24(2 suppl 41):S48–S59.
  17. Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995; 21:1041–1058.
  18. Chun YS, Park SJ, Park IK, Chung H, Lee J. The clinical and ocular manifestations of Takayasu arteritis. Retina 2001; 21:132–140.
  19. Maksimowicz-McKinnon K, Hoffman GS. Large-vessel vasculitis. Semin Respir Crit Care Med 2004; 25:569–579.
  20. Umehara I, Shibuya H, Nakagawa T, Numano F. Comprehensive analysis of perfusion scintigraphy in Takayasu's arteritis. Clin Nucl Med 1991; 16:352–357.
  21. Werfel T, Kuipers JG, Zeidler H, Kapp A, Kiehl P. Cutaneous manifestations of Takayasu arteritis. Acta Derm Venereol 1996; 76:496–497.
  22. Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients [published online ahead of print July 10, 2013]. Mayo Clin Proc 2013; 88:822–830. doi:10.1016/j.mayocp.2013.04.025.
  23. Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis: a preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998; 66(suppl 1):S191–S195.
  24. Hoffman GS. Takayasu arteritis: lessons from the American National Institutes of Health experience. Int J Cardiol 1996; 54(suppl):S99–S102.
  25. Steeds RP, Mohiaddin R. Takayasu arteritis: role of cardiovascular magnetic imaging [published online ahead of print July 5, 2005]. Int J Cardiol 2006; 109:1–6. doi:10.1016/j.ijcard.2004.09.023.
  26. Tso E, Flamm SD, White RD, Schvartzman PR, Mascha E, Hoffman GS. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002; 46:1634–1642.
  27. Pipitone N, Versari A, Salvarani C. Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update [published online ahead of print February 21, 2008]. Rheumatology (Oxford) 2008; 47:403–408. doi:10.1093/rheumatology/kem379.
  28. Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005; 46:917–922.
  29. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17:16–24.
  30. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes: American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990; 33:1074–1087.
  31. Cid MC, Font C, Coll-Vinent B, Grau JM. Large vessel vasculitides. Curr Opin Rheumatol 1998; 10:18–28.
  32. Olin JW, Froehlich J, Gu X, et al. The United States Registry for fibromuscular dysplasia: results in the first 447 patients [published online ahead of print May 21, 2012]. Circulation 2012; 125:3182–3190. doi:10.1161/CIRCULATIONAHA.112.091223.
  33. Kötter I, Henes JC, Wagner AD, Loock J, Gross WL. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature [published online ahead of print May 11, 2012]. Clin Exp Rheumatol 2012; 30(1 suppl 70):S114–S129.
  34. Koening CL, Langford CA. Novel therapeutic strategies for large vessel vasculitis. Rheum Dis Clin North Am 2006; 32:173–186, xi.
  35. Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Yamashita S. Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 2005; 143:394–395.
  36. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Arthritis Rheum 2008; 67:1567–1569.
  37. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on the use of biologic therapies. Curr Opin Rheumatol 2014; 26:7–15.
  38. Youngstein T, Peters JE, Hamdulay SS, et al. Serial analysis of clinical and imaging indices reveals prolonged efficacy of TNF-a and IL-6 receptor targeted therapies in refractory Takayasu arteritis [published online ahead of print September 30, 2013]. Clin Exp Rheumatol.
  39. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center [published online ahead of print November 1, 2013]. J Rheumatol 2013; 40:2047–2051. doi:10.3899/jrheum.130536.
  40. Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 2013; 54:405–411.
  41. Goel R, Danda D, Kumar S, Joseph G. Rapid control of disease activity by tocilizumab in 10 'difficult-to-treat' cases of Takayasu arteritis. Int J Rheum Dis 2013; 16:754–761.
  42. Inder SJ, Bobyshev YV, Cherian SM, et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immunoinflammatory reactions. Cardiovasc Surg 2000; 8:141–148.
  43. Park MC, Park YB, Jung SY, Lee KH, Lee SK. Anti-endothelial cell antibodies and antiphospholipid antibodies in Takayasu's arteritis: correlations of their titers and isotype distributions with disease activity. Clin Exp Rheumatol 2006; 24(2 suppl 41):S10–S16.
  44. Hoyer BF, Mumtaz IM, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab [published online ahead of print September 27, 2011]. Ann Rheum Dis 2012; 71:75–79. doi:10.1136/ard.2011.153007.
  45. Galarza C, Valencia D, Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008; 34:124–128.
  46. Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witt T. Remission achieved in refractory advanced Takayasu arteritis using rituximab [published online ahead of print October 10, 2012]. Case Rep Rheumatol 2012; 2012:406963. doi:10.1155/2012/406963.
  47. Liang P, Tan-Ong M, Hoffman GS. Takayasu's arteritis: vascular interventions and outcomes. J Rheumatol 2004; 31:102–106.
  48. Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience [published online ahead of print January 9, 2012]. Circulation 2012; 125:813–819. doi:10.1161/CIRCULATIONAHA.111.058032.
  49. Perera A, Youngstein T, Gibbs RG, Jackson JE, Wolfe JH, Mason JC. Optimizing the outcome of vascular intervention for Takayasu arteritis. Br J Surg 2014; 101:43–50.
  50. Lee GY, Jeon P, Do YS, et al. Comparison of outcomes between endovascular treatment and bypass surgery in Takayasu arteritis [published online ahead of print October 18, 2013]. Scand J Rheumatol 2014; 43:153–161. doi:10.3109/03009742.2013.822096.
  51. Qureshi MA, Martin Z, Greenberg RK. Endovascular management of patients with Takayasu arteritis: stents versus stent grafts. Semin Vasc Surg 2011; 24:44–52.
  52. Park MC, Lee SW, Park YB, Lee SK, Choi D, Shim WH. Post-interventional immunosuppressive treatment and vascular restenosis in Takayasu's arteritis [published online ahead of print December 13, 2005]. Rheumatology (Oxford) 2006; 45:600–605. doi:10.1093/rheumatology/kei245.
  53. Miyata T, Sato O, Koyama H, Shigematsu H, Tada Y. Long-term survival after surgical treatment of patients with Takayasu's arteritis [published online ahead of print September 2, 2003]. Circulation 2003; 108:1474–1480. doi:10.1161/01.CIR.0000089089.42153.5E.
  54. Lagneau P, Michel JB, Vuong PN. Surgical treatment of Takayasu's disease. Ann Surg 1987; 205:157–166.
  55. Seth S, Goyal NK, Jagia P, et al. Carotid intima-medial thickness as a marker of disease activity in Takayasu's arteritis [published online ahead of print June 20, 2005]. Int J Cardiol 2006; 108:385–390. doi:10.1016/j.ijcard.2005.05.033.
  56. Ng WF, Fantin F, Ng C, et al. Takayasu's arteritis: a cause of prolonged arterial stiffness [published online ahead of print January 10, 2006]. Rheumatology (Oxford) 2006; 45:741–745. doi:10.1093/rheumatology/kei274.
  57. de Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis [published online ahead of print May 8, 2010]. Circ J 2010; 74:1236–1241. doi:10.1253/circj.CJ-09-0905.
  58. Lee K, Kang WC, Ahn T, et al. Long-term outcome of drug-eluting stent for coronary artery stenosis in Takayasu's arteritis [published online ahead of print May 13, 2010]. Int J Cardiol 2010; 145:532–535. doi:10.1016/j.ijcard.2010.04.066.
  59. Yokota K, Shimpo M, Iwata T, et al. A case of Takayasu arteritis with repeated coronary artery restenosis after drug-eluting stent implantation successfully treated with a combination of steroids [published online ahead of print April 1, 2012]. Intern Med 2012; 51:739–743. .doi:10.2169/internalmedicine.51.6344.
  60. Spacek M, Zimolova P, Veselka J. Takayasu arteritis: use of drug-eluting stent and balloon to treat recurring carotid restenosis. J Invasive Cardiol 2012; 24:E190–E192.
  61. Soeiro AM, Pinto AL, Henares BB, Ribeiro HB, Lima FG, Serrano CV Jr. Takayasu arteritis: stenosis after bare-metal and drug-eluting stent implantation. Arq Bras Cardiol 2013; 100:e8–e11.
  62. Agarwal G, Vats HS, Raval AN, Yevzlin AS, Chan MR, Gimelli G. Chronic total occlusion and successful drug-eluting stent placement in Takayasu arteritis-induced renal artery stenosis [published online ahead of print May 8, 2013]. Clin Med Res 2013; 11:233–236. doi:10.3121/cmr.2013.1132.

Back to Top